Murex Pharmaceuticals Licenses Ariadne’s Pathway Studio Software Solution To Be Utilized For Cancer Therapeutics Development

Ariadne Genomics, Inc. today announced that Murex Pharmaceuticals (Dallas, Texas) has licensed its Pathway Studio® software solution for the visualization and analysis of biological pathways and gene regulation networks. Murex will use Pathway Studio to develop computer-based models for the identification and validation of cancer targets.

ROCKVILLE, Md. (PRWEB) July 27, 2006 -- Ariadne Genomics, Inc. today announced that Murex Pharmaceuticals (Dallas, Texas) has licensed its Pathway Studio® software solution for the visualization and analysis of biological pathways and gene regulation networks. Murex will use Pathway Studio to develop computer-based models for the identification and validation of cancer targets.

Pathway Studio (formerly known as PathwayAssist) enables life scientists to identify relationships among proteins, small molecules, cell processes and treatments, and automatically extract relevant biological interactions from scientific literature. With the product’s resident ResNet database of over 1,000,000 interactions extracted from PubMed and approximately 1000 predefined pathways, researchers can easily reconstruct regulatory networks from their microarray and proteomics data, identify biomarkers, and model drug responses.

“It’s hard to overestimate the importance of Pathway Studio in our development of cancer therapies based on patients’ individual gene expression data,” commented David Shanahan, President and CEO of Murex Pharmaceuticals. “Pathway Studio will accelerate our development efforts as well as help to further increase the safety of our products”.

“Pathway Studio is a must-have tool for cancer target research,” added Ilya Mazo, President of Ariadne. “The software keeps the on-board ResNet database up-to-date, automatically extracting relevant biological interactions from literature, while the flexible user interface allows database queries to expand known pathways and build regulatory networks focused on specific research tasks, such as drug target or biomarker discovery.”

Pathway Studio is available as a desktop or workgroup solution. A 20 day fully functional trial version can be found on the Ariadne website at www.ariadnegenomics.com.

About Murex Pharmaceuticals

Murex Pharmaceuticals is a privately held biotechnology company dedicated to developing cancer therapies based on an individual’s tumor biology. The company is headquartered in Dallas, Texas, with research and development efforts underway at labs in Boston, Massachusetts, Carrollton, Texas, and San Francisco, California.

About Ariadne

Ariadne develops systems biology software for life science research. Products include Pathway Studio® (formerly PathwayAssist) leading pathway analysis software and PathwayExpert™ informatics platform for the research of cellular regulation and drug response modeling. Ariadne software is equipped with MedScan™, a mature information extraction technology based on domain-specific natural language processing (NLP), and comes with a ResNet family of molecular network databases, both automatically generated and manually curated. MedScan Reader™ is a biomedical literature browser that greatly facilitates the reading of scientific text by automatically extracting and displaying the information of interest.

###


Contact Information
Natalia Alexandrova
ARIADNE GENOMICS
http://www.ariadnegenomics.com
240-453-6296

Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy